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Background: Epinephrine is a first-line drug for cardiopulmonary resuscitation, but its efficacy in the treatment
of bupivacaine-induced cardiac toxicity is still in question. We hypothesized that epinephrine can reverse cardiac
inhibition of bupivacaine by modulating ion flows through the ventricular myocyte membrane channels of rats. The
aim of this study was to observe and report the effects of epinephrine on high-concentration bupivacaine-induced
inhibition of sodium (INa), L-type calcium (ICa-L), and transient outward potassium (Ito) currents in the ventricular
myocytes of rats.
Methods: The ventricular myocytes were isolated from Sprague-Dawley rats (250-300 g) by acute enzymatic
dissociation. The whole-cell patch clamp technique was used to record the ion channel currents in single ventricular
myocytes both before and after administration of medications.
Result: Administration of bupivacaine 100 μmol/L significantly reduced INa, (P < 0.05). However, administration of
bupivacaine 100 μmol/L in conjunction with epinephrine 0.15 μg/ml had no effect in restoring INa to its previous
state. Similarly, a sharp decline of ICa-L and Ito was observed after administration of bupivacaine 100 μmol/L (P < 0.05).
In contrast to INa, ICa-L and Ito were significantly improved after the administration of the aforementioned combination
of bupivacaine and epinephrine (P < 0.05).
Conclusion: Epinephrine can reverse high-concentration bupivacaine induced inhibition of ICa-L and Ito, but not INa.
Thus, epinephrine’s effectiveness in reversal of bupivacaine-induced cardiac toxicity secondary to sodium channel
inhibition may be limited.
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Epinephrine is a first-line drug for cardiopulmonary re-
suscitation. However, the extent of its effectiveness in
bupivacaine-induced cardiac toxicity has remained unre-
solved [1-4]. Weinberg et al. [1] and Hiler et al. [2] repor-
ted that using epinephrine for resuscitation may increase
myocardial oxygen consumption in the bupivacaine* Correspondence: xuzhong@263.net
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setting may result in refractory ventricular fibrillation,
pulmonary edema, acidosis, hypoxemia and other com-
plications. On the other hand, Harvey et al. [3] claimed
that epinephrine was necessary for circulatory recovery
in their rabbit model of bupivacaine toxicity. Their
claim was supported by work that demonstrated that
epinephrine can accelerate hemodynamic recovery [4],
reverse slowed action potential conduction, shorten action
potential duration, and improve myocardial contractilitys is an Open Access article distributed under the terms of the Creative Commons
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caine [5].
Accidental intravascular injection of bupivacaine, over-
absorption from peripheral tissues, and high plasma con-
centrations contribute to life-threatening cardiac rhythm
disturbances. Previous studies suggested that the mechan-
ism of bupivacaine-induced cardiac toxicity was secondary
to its depression of the cardiac conduction system [6]
through inhibition of the sodium channels [7,8] potassium
channels [9,10] and calcium channels [11,12].
We hypothesized that epinephrine can reverse bupiva-
caine-induced cardiac inhibition by modulating INa, ICa-L,
and Ito membrane channels of ventricular myocytes. We
used the whole-cell patch clamp technique to observe the
effect of epinephrine on these membrane channels in rat
ventricular myocytes that were subjected to high-concen-
tration bupivacaine-induced cardiac toxicity.
Methods
Isolated heart and preparation
Ths study was approved by the Animal Care and Use
Committee of Wenzhou Medical College. Adult Male
Sprague-Dawley rats, weighing 250 to 300 g, were anes-
thetized using 5% chloral hydrate (7 ml/kg intraperitio-
neal injection). The carotid artery is cut to allow rapid
and thorough exsanguination. The hearts were rapidly
removed intact with a short aortic remnant. While in
this Tyrode solution the aorta is cannulated, one should
make sure that there are no air bubbles trapped in the
cannula. The cannulated heart is then mounted on a
Langendorff perfusion apparatus with constant flow.
After rapid excision, the heart was mounted in a modi-
fied Langendorff system and then perfused with the
nominally Ca2 + -free Tytode solution (NaCl 137 mM、KCl
5.4 mM、MgCl2 1.0 mM、NaH2PO4 0.33 mM、HEPES
10 mM、Glucose 10 mM, and PH7.35 with NaOH) for
5 min at room temperature (20-25)°C. The perfusate
reservoirs and column are glass jacketed, allowing the
temperature to be maintained at 37°C by means of a re-
circulating water bath. All of the perfusion solutions are
equilibrated with 100% oxygen. The heart is then retro-
gradely perfused with the nominally Ca2 + -free Tyrode
solution which causes cessation of the heartbeat until
the blood is washed out. This was followed by perfusion
with enzyme solution, containing 1 mg/ml collagenase
(Sigma, typeI) in nominally Ca2 + -free Tytode solution,
followed for 10 ~ 15 min. The softened heart was re-
moved from the column, and the left ventricle was dis-
sected in modified KB (KCl 40 mM, KH2PO4 20 mM,
MgSO4 3.0 mM, KOH 80 mM, Glutamate 50 mM,
Taurine 20 mM, HEPES 10 mM, glucose 10 mM, EGTA
0.5 mM, and pH 7.35 with KOH). The cells were main-
tained in modified KB solution and stabilized at room
temperature for 1 hour.Equipments and methods
An EPC-10 patch clamp amplifier (HEKA, Germany)
was used for application of the whole-cell patch clamp
in the ventricular myocytes. Pulse stimulation and data
acquisition were recorded by Pulse 8.0 software (HEKA,
Germany). Patch pipettes were pulled from glass tubing
with a 1.5 mm outer diameter (SUTTER, USA) by the
use of micro-electrodes (P-97, SUTTER, USA), and the
tip was heated to give a resistance of 1.5-2.5 MΩ when
filled with the specific, appropriate solution (see below).
Using an inverted microscope, microelectrodes were di-
rected to the ventricular myocytes by a three-dimensional
micromanipulator (MP-285, SUTTER, USA). A Giga-seal
was formed after vacuum suction. The patch membrane
was broken after fast capacitance compensation by the
provision of additional suction with subsequent cons-
truction of a whole-cell recording. To reduce the instant-
aneous current charging/discharging, and to minimize
clamping errors, the slow capacitance compensation and
series resistance compensation were settled at 70% - 80%.
Leakage currents were subtracted by the P/4 method.
Electrophysiology
1. For recording INa, the external solution was com-
posed of the following, in mM: Choline-Cl 120, NaCl 20,
MgCl2 1.0, HEPES 5, Glucose 10, CsCl 4.6, pH 7.35 with
CsOH. the internal solution was composed of the follow-
ing, in mM: CsCl 120、NaCl 10、MgCl2 1.0、Na2ATP
5.0、EGTA 10、HEPES 10, pH 7.3 with CsOH.
The potential was held at -90 mV, INa was evoked by
25 ms, and accompanied by -30 mV square-wave de-
polarizing pluses. The stimulation program of current
density-voltage curve was as follows: under a holding
potential (Vh) of -90 mV, the step clamp voltage (Vs)
was stimulated from -90 mV to +50 mV by a step of 10
mV with a 50 ms duration, and a 0.2 Hz stimulation
frequency.
2. For recording ICa-L, the external solution was com-
posed of the following, in mM: Choline-Cl 140, MgCl2
1.0, CaCl2 2.0, HEPES 5, Glucose 10, CsCl 4.6, TEA-Cl
10, pH 7.35 with CsOH. the internal solution was com-
posed of the following, in mM: CsCl 120、MgCl2
1.0、MgATP 5.0、EGTA 10、HEPES 10 TEA-Cl 10,
pH 7.3 with CsOH.
The potential was held at -40 mV, and ICa-L was
evoked by 150 ms, accompanied by 0 mV square-wave
depolarizing pluses. The stimulation program of current
density-voltage curve was as follows: under a Vh of -40
mV, the Vs was stimulated from -40 mV to +50 mV by a
step of 10 mV with a 250 ms duration, and a 0.2 Hz
stimulation frequency.
3. For recording Ito, the external solution was com-
posed of the following, in mM: NaCl 137, KCl 5.4, CaCl2
1.8, MgCl2 1.0, NaH2PO4 0.33, HEPES 10, Glucose 10,
Table 1 Bupivacaine alone and combination with
epinephrine affect the channels current-density
Channel current Cell number TO (pA/pF) T1 (pA/pF) T2 (pA/pF)
INa 5 −8.3 ± 0.9 −2.2 ± 0. 6 −2.3 ± 0.7
ICa-L 6 −7. 8 ± 0.7 −2.0 ± 0.6 −4.9 ± 0.9
Ito 6 23 ± 5 15 ± 3 26 ± 8
Data were shown as mean ± SD. T0 = before the bupivacaine perfusion; T1 = after
the perfusion of the 100 μmol/L bupivacaine; T2 = after the perfusion of the
100 μmol/L bupivacaine with 0.15 μg/ml epinephrine.
INa: T1 vs T0, P < 0.001; T2 vs T1, P >0.05.
ICa-L: T1 vs T0, P < 0.001; T2 vs T1, P < 0.001.
Ito: T1 vs T0, P < 0.05; T2 vs T1, P < 0.05.
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composed of the following, in mM: KCl 140、MgCl2
1.0、K2ATP 5.0、EGTA 10、HEPES 5,pH 7.3 with KOH.
The potential was held at -90 mV, Ito was evoked by
20 ms, 50 mV square-wave depolarizing pluses. The sti-
mulation program of current density-voltage curve was:
under a Vh of -90 mV, and INa was eliminated by 20 ms,
with -40 mV depolarizing pluses; the Vs was stimulated
from -40 mV to +50 mV by a step of 10 mV with a 400
ms duration and a 0.2 Hz stimulation frequency.
A control curve of I-V was collected before drug perfu-
sion (T0). Then 100 umol/L bupivacaine and the mixture
of 100 umol/L bupivacaine and 0.15 μg/ml epinephrine
were added into the reservoirs respectively from super-
fusion systerm (DADVC-8PP,ALA SCIENTIFIC, USA).
The DAD-VC systems go out with a Micromanifold con-
sisting of 8 tubes of polyamide coated quartz glass of 100
um ID. The Micromanifold enables up to 8 solutions from
the reservoirs to flow into a small common space of less
than 1ul. The Micromanifold with a micromanipulator
can easily be moved around the cell preparation and
pointed at the target cell. The user must be careful to aim
the output so that it completely bathes the cell under
study. So during the study there is no motion of the out-
put tip to be dealt with and there is no need to have all
the solutions flowing out and contaminating the prepar-
ation solution during an experiment. After the cell surface
perfusion with 100 μmol/L bupivacaine for 10 seconds.
The peak current and I-V curve were recorded (T1). The
microperfusion tube was then swithed by another reser-
voir prefilled with 100 μmol/L bupivacaine and 0.15 ug/ml
epinephrine after the model was successfully made by 100
μmol/L bupivacaine. The peak current and I-V curve were
then recorded at the time (T2) when the cells’ surface
were perfusion with 100 μmol/L bupivacaine and 0.15
ug/ml epinephrine for 10 seconds.
To eliminate the error among cells, the size of the ion
currents was represented by the current density, which
was the ratio of current intensity and cell membrane
capacitance (pA/pF). Data were stored in the hard disk
for the measurement and analysis. Raw current data were
analyzed and measured by pulse 8.0.
Statistical analysis
All data were analyzed using SPSS 13.0 and presented as
mean ± SD. The results were analyzed with a paired t
test, the P value were using the Bonferroni correction,.
A P value < 0.05 was considered statistical significance.
The graphs were performed by Origin 8.0.
Results
The various ion currents could be obtained from the
fresh isolated ventricular myocytes, which indicated that
the cells had good electrophysiological properties.Effects of epinephrine on bupivacaine-induced inhibition
of sodium currents in ventricular myocytes of rats
Sodium currents: The INa at T0, T1, and T2 was (-8.3 ± 0.9)
(pA/pF), (-2.2 ± 0. 6) (pA/pF), and (-2.3 ± 0.7) (pA/pF), re-
spectively (n = 5, T1 vs T0, P < 0.001; T2 vs T0, P < 0.001;
T2 vs T1, P =0.322) (Table 1). Figure 1 depicts the effects
of bupivacaine alone and in combination with epinephrine
on the INa trace.
Sodium channel current density-voltage curve: The
activation potential of INa was -60 mV, with a peak poten-
tial of -30 mV and a reverse potential of +20 mV. Bupiva-
caine 100 μmol/L present in the perfusate lead to the INa
decrease, and an upper shift of the current density-voltage
curve, without changing the peak potential, activation po-
tential, or the reversal potential. Administration of bupi-
vacaine 100 μmol/L and epinephrine 0.15 μg/ml did not
effect any change in the INa current density-voltage curve
(Figure 2).
Effects of epinephrine on bupivacaine-induced inhibition
of L-type calcium currents in ventricular myocytes of rats
L-type calcium currents: The ICa-L at T0, T1, and T2 was
(-7.8 ± 0.7) (pA/pF), (-2.0 ± 0. 6) (pA/pF), and (-4.9 ± 0.9)
(pA/pF), respectively (n = 6, T1 vs T0, P < 0.001; T2 vs T0,
P < 0.001; T2 vs T1, P < 0.001). Figure 3 depicts the effects
of bupivacaine 100 μmol/L alone and in combination with
epinephrine 0.15 μg/ml on the ICa-L trace.
ICa-L was -30 mV, with a peak potential of 0 mV and a
reverse potential of +40 mV. Bupivacaine 100 μmol/L
present in the perfusate contributed to the upper shift of
the current density - voltage curve without changing the
activation potential and the curve shape. However, bupi-
vacaine 100 μmol/L in combination with epinephrine 0.15
μg/ml increased the ICa-L current, and moved the current
density-voltage curve of ICa-L downward (Figure 4).
Effects of epinephrine on bupivacaine-induced inhibition
of transient outward potassium currents in ventricular
myocytes of rats
Transient outward potassium currents: The current
density of Ito at T0, T1, and T2 was (23 ± 5) (pA/pF),
Figure 1 Representative INa traces obtained from ventricular myocytes groups: control, bupivacaine 100 μmol/L alone, and bupivacaine with
epinephrine 0.15 μg/ml. Family of current traces obtained by applying a series of 50 ms pulses ranging from -90 mV to 50 mV with a holding
potential of -90 mV.
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T1 vs T0, P =0.013; T2 vs T0, P = 0.161; T2 vs T1, P =0.003).
Figure 5 depicts the effects of bupivacaine 100 μmol/L
alone, and in combination with epinephrine 0.15 μg/ml
on the Ito trace.Figure 2 The INa current-voltage relationship in the absence of bupivacain
combination with epinephrine 0.15 μg/ml. Bupivacaine 100 μmol/L present in
curve. Administration of 100 μmol/L bupivacaine and epinephrine 0.15 μg/mTransient outward potassium channel currents density-
voltage curves: The activation potential of Ito was at -40
mV with the higher voltage the current was increased,
and the outward rectification characteristics were evident.
Bupivacaine 100 μmol/L without epinephrine decreasede, with bupivacaine 100 μmol/L alone, and bupivacaine 100 μmol/L in
the perfusate contributed to an upper shift of the current density-voltage
l did not effect any change in the curve.
Figure 3 Representative ICa traces obtained from ventricular myocytes groups: control, bupivacaine 100 μmol/L alone, and bupivacaine 100 μmol/L in
combination with epinephrine 0.15 μg/ml. Family of current traces obtained by applying a series of 250 ms pulses ranging from -40 mV to 50 mV with
a holding potential of -40 mV.
Figure 4 The ICa-L current-voltage relationship in the absence of bupivacaine, with bupivacaine 100 μmol/L alone, and bupivacaine 100 μmol/L in
combination with epinephrine 0.15 μg/ml. Bupivacaine 100 μmol/L present in the perfusate contributed to an upper shift of the current density - voltage
curve without changing the activation potential and the curve shape. However, bupivacaine 100 μmol/L in combination with epinephrine 0.15 μg/ml
increased the ICa-L current and moved the curve of ICa-L downward.
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Figure 5 Representative Ito traces obtained from ventricular myocyte groups: control, bupivacaine 100 μmol/L alone, and bupivacaine 100 μmol/L in
combination with epinephrine 0.15 μg/ml. Family of current traces obtained by applying a series of 20ms test pulses of -40 mV to eliminate current
through Na channels, which was then evoked by a series of 400 ms pulses ranging from -40 mV to 50 mV with a holding potential of -90 mV.
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bupivacaine 100 μmol/L in combination with epinephrine
0.15 μg/ml. However, both their rectifier characteristics
were not changed (Figure 6).
Discussion
This study demonstrates that epinephrine can reverse
bupivacaine-induced inhibition of calcium channels and
the transient outward current of the potassium channels
in the ventricular myocytes of rats, but with no significant
effect on improving ionic flow in the sodium channels, i.e.,
reversing its inhibition.
Epinephrine is a potent heart stimulant. Currently, the
American Heart Association recommends use of epi-
nephrine during CPR [13], as a first-line drug for treat-
ing cardiac arrest, however, the use of epinephrine for
bupivacaine-induced cardiac toxicity remains controver-
sial [1-4].
The essence of bupivacaine-induced cardiac toxicity
involves its ability to block myocardial cell ion channels.
Rapid intravenous injection of a clinical dose of bupiva-
caine may lead to a cardiac arrest secondary to high
plasma concentrations of bupivacaine that reach ≥ 100
μmol/L in a short period of time [14]. Thereby it redu-
cing the amplitude of the myocardial action potential,
shortening the action potential duration [12], and signifi-
cantly inhibiting the myocardial sodium [6], potassium[8] and calcium [11] channel function. Moreover, while
our results confirm these findings, we also have electro-
physiological confirmation that epinephrine alone may
be of little use in regard to sodium channel “resusci-
tation” as opposed to its ability to aid the calcium or po-
tassium channels. Discussion of our study’s impact on
the sodium, calcium, and potassium channels is warranted
at this juncture.
INa facilitates the depolarization of the action potential
(phrase 0), which affects excitability, refractoriness and
conductivity of myocardial cells. Depolarizing of this
action potential is impeded by bupivacaine, and its car-
diac toxicity is directly related to the impaired flow Na+
inflow, which results in conduction disturbances and a
series of cardiac arrhythmias [6] that may lead to car-
diac arrest. A plasma bupivacaine concentration of 100
μmol/L blocks 73% of the sodium current. Catecholamine
impact on the Na+ currents remains controversial. Wang
[15] and Gintant [16] indicate that β-receptor agonists
increase the sodium current, while others report that
high concentrations of isoproterenol (a ß agonist) can
produce inhibition of Na+ currents [17]. Our results in-
dicate that epinephrine does not effectively support the
recovery of ionic flow in the bupivacaine-inhibited sodium
channels. This suggests that the use of epinephrine in
reversing bupivacaine-induced cardiac toxicity may have
limitations.
Figure 6 The Ito current-voltage relationship in the absence of bupivacaine, with 100 μmol/L bupivacaine alone, and 100 μmol/L bupivacaine in
combination with epinephrine 0.15 μg/ml. Bupivacaine 100 μmol/L without epinephrine decreased Ito. On the other hand, Ito increased in response to
the bupivacaine 100 μmol/L in combination with epinephrine 0.15 μg/ml.
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action potential plateau by increasing intracellular calcium
and myocardial contraction. There is a concentration-
dependent relationship between bupivacaine and its in-
hibition of L-type calcium channels in rat ventricular
myocytes. A bupivacaine concentration of 100 μmol/L
is roughly equivalent to the IC50 inhibition of ICa-L [11].
The inhibitory effect of ICa-L in our study was 50%
higher than that reported in the literature and this may
be related to our method of drug perfusion. We ensured
that the bupivacaine concentration on the surface of the
cell membrane reached 100 μmol/L instantly by using a
direct microperfusion system. The cells in this case
lacked a process of gradual adaptation, which may have
enhanced the inhibitory effect on the channels. This
situation may be analogous with the clinical picture of
acute bupivacaine toxicity. Although β-adrenergic ago-
nists can augment the frequency of ionic channel open-
ing and current passage through the L-type calcium
channel [18,19], there are no published reports as to
whether epinephrine can reverse bupivacaine-induced
inhibition of calcium channels. In our study bupivacaine
suppressed the calcium current, but this current was
partially restored by epinephrine. Thereby contributing
to improved myocardial contractility and physiologic
recovery.
With the rapid activation and inactivation in the early
repolarization period of the action potential, Ito exhibited
a concentration-dependent inhibition by bupivacaine on
ventricular myocytes [8]. In humans, the inhibition of Itoprolongs the repolarization of the myocardial action po-
tential and reduces the excitation-contraction coupling
efficiency of the myocardial cells. Thus weakening the
cardiac contractility by impairing regulation of the sarco-
plasmic reticulum’s calcium load, releasing and influencing
the function of the L-type calcium channel, and impairing
the sodium calcium exchange mechanism. Additionally,
the Ito of rat ventricular myocytess can be partially inhib-
ited by α1-adrenergic receptor agonists [20]. However, our
study demonstrates that epinephrine can reverse the inhib-
ition of Ito induced by bupivacaine. Through the enhance-
ment of the calcium current and an increased intracellular
Ca2+ concentration secondary to activated β adrenergic
receptors, there is a resultant increase in cardiac contract-
ility through the indirect recovery of calcium-dependent
Ito [21].
In this study we used the dose of epinephrine 0.15 μg/
ml, which was based on our previous work demonstrating
that isolated, arrested rats hearts recovered with this par-
ticular dose [22]. Additionally, we added bupivacaine 100
μmol/L to avoid bupivacaine elution in the process of
extracellular fluid perfusion on the cell’s surface in order
to simulate a setting where there is a critical plasma con-
centration of bupivacaine that induces cardiac toxicity.
The results/conclusions of our study are limited by the
fact that we did not observe any reversal effect of epi-
nephrine on the inhibition of sodium channel induced
by different concentrations of bupivacaine, and we did
not observe any reversal of the inhibitory effect of differ-
ing concentrations of epinephrine on the ion channels.
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Epinephrine can reverse high-concentration bupivacaine-
induced inhibition of calcium channels and the transient
outward potassium current channels in the ventricular
myocytes of rats, whereas it has no significant effect on
improving sodium channel ionic flows. Thereby providing
no augmentation of its action potential depolarization.
These findings support the position that the use of
epinephrine alone in the resuscitation of bupivacaine-
induced cardiac toxicity/arrest may be of limited value
in that it may produce a less than optimal result. It may
be that adjunctive therapies/medications are needed
to augment the use of epinephrine in the setting of
bupivacaine-induced cardiac toxicity/arrest.
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